Vinpocetine inhibits breast cancer cells growth in vitro and in vivo
- 662 Downloads
Vinpocetine is a clinically used drug for cerebrovascular disorders as well as age-related memory impairment. Of note, vinpocetine has been recently identified as a novel anti-inflammatory agent; however, its effects on cancer cells remain to be investigated. In the present study, we found that vinpocetine potently inhibited proliferation of multiple types of human breast cancer cells by arresting cell cycle at G0/G1 phase. It was also revealed that vinpocetine induced cell apoptosis via mitochondria-dependent pathway. Moreover, vinpocetine impaired the migration of the strongly metastatic cell MDA-MB-231. In xenograft model of human breast cancer in nude mice, both systemic and local administration of vinpocetine significantly suppressed the tumor growth without observed toxicity. Interestingly, vinpocetine markedly attenuated the activation of Akt and signal transducer and activator of transcription factor 3 (STAT3), but had no effects on MAP kinases pathways. Collectively, the data suggest that vinpocetine possesses significant yet previously unknown antitumor properties that may be utilized for the treatment of breast cancer.
KeywordsVinpocetine Breast cancer Proliferation Apoptosis STAT3
This work was supported by the National Natural Science Foundation of China (No.30900530), Doctoral Fund of Ministry of Education (for young teachers) of China (No.20090171120055); the Fundamental Research Funds for the Central Universities (No.50000-3161020).
- 25.Prall OW, Sarcevic B, Musgrove EA, Watts CK, Sutherland RL (1997) Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 272:10882–10894PubMedCrossRefGoogle Scholar
- 38.Ahn HS, Crim W, Pitts B, Sybertz EJ (1992) Calcium-calmodulin-stimulated and cyclic-GMP-specific phosphodiesterases. Tissue distribution, drug sensitivity, and regulation of cyclic GMP levels. Adv Second Messenger Phosphoprot Res 25:271–288Google Scholar